NASDAQ / LIVE COMPANY INTELLIGENCE

Alnylam Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERALNY
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ALNY COVERAGE

What’s moving Alnylam Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

The story matters when it changes Alnylam Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced

The story matters when it changes Alnylam Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 earnings call transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 earnings call transcript

Investors are testing whether Alnylam Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

The story matters when it changes Alnylam Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

Investors are testing whether Alnylam Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ALNY filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-30 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-04-30 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-12 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-30SEC ↗8-KMaterial company eventFiled 2026-05-27 · Period 2026-05-20SEC ↗8-KMaterial company eventFiled 2026-04-30 · Period 2026-04-30SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-06 · Period 2026-05-20SEC ↗4Official SEC filingFiled 2026-06-03 · Period 2026-06-01SEC ↗
EARNINGS / QUARTERLY TRACKER

Alnylam Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.